--- title: "3 'Strong Buy' Stocks to Buy Now, 2/6/2026, According to Top Analysts" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/275127565.md" description: "Three stocks have received 'Strong Buy' ratings from top analysts: Spruce Biosciences (SPRB) with a price target of $220, implying a 200.64% upside; Adaptive Biotechnologies (ADPT) with a target of $21, suggesting a 25.99% upside; and JFrog (FROG) with a target of $74, indicating a 51.92% upside. These ratings are based on recent analyst updates, highlighting their potential for significant growth." datetime: "2026-02-06T12:31:53.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275127565.md) - [en](https://longbridge.com/en/news/275127565.md) - [zh-HK](https://longbridge.com/zh-HK/news/275127565.md) --- > 支持的语言: [English](https://longbridge.com/en/news/275127565.md) | [繁體中文](https://longbridge.com/zh-HK/news/275127565.md) # 3 'Strong Buy' Stocks to Buy Now, 2/6/2026, According to Top Analysts Looking for top-rated stocks to buy now? Based on recent analyst updates, the three companies below have all earned Strong Buy ratings from Top Wall Street Analysts. Each offers meaningful upside potential, backed by new Buy calls. ### Claim 50% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential For more ideas, you can explore TipRanks' Analyst Top Stocks tool, which tracks the latest Buy ratings from top-performing analysts in real time. Here are today's top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio. **Spruce Biosciences** (SPRB) – Spruce Biosciences is a clinical-stage biopharmaceutical company focused on developing treatments for rare endocrine disorders. Today, H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on the stock with a price target of $220 per share. In the last three months, all three Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 200.64%. **Adaptive Biotechnologies** (ADPT) – This is a biotech firm focused on immune-based tests for cancer and immune diseases. Today, TD Cowen analyst Daniel Brennan maintained a Buy rating on the stock and increased the price target from $20 to $21 per share. Interestingly, five out of the six Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 25.99%. **JFrog** (FROG) – JFrog is a software company that provides tools to manage and secure code used in app development. Today, Bank of America Securities analyst Koji Ikeda maintained a Buy rating on the stock with a price target of $74 per share. Interestingly, 17 out of the 19 Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 51.92%. ## **Who Are the Top Analysts?** TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time. **See real-time analyst rankings and learn more about the performance of Top Analysts on TipRanks'** **Top Wall Street Analysts** **page.** ### 相关股票 - [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) - [iShares Expanded Tech Software Sector ETF (IGV.US)](https://longbridge.com/zh-CN/quote/IGV.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [Spruce Biosciences (SPRB.US)](https://longbridge.com/zh-CN/quote/SPRB.US.md) - [Adaptive Biotechnologies (ADPT.US)](https://longbridge.com/zh-CN/quote/ADPT.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [Direxion S&P Biotech Bear 3X (LABD.US)](https://longbridge.com/zh-CN/quote/LABD.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [SPDR S&P Software (XSW.US)](https://longbridge.com/zh-CN/quote/XSW.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [JFrog (FROG.US)](https://longbridge.com/zh-CN/quote/FROG.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md) - [ISHRS S&P Glb It (IXN.US)](https://longbridge.com/zh-CN/quote/IXN.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md) ## 相关资讯与研究 - [Deep Dive Into Avantor Stock: Analyst Perspectives (7 Ratings)](https://longbridge.com/zh-CN/news/278115898.md) - [Design Therapeutics reports lower-than-expected Q4 net loss](https://longbridge.com/zh-CN/news/278441864.md) - [Spruce Biosciences 10-K: $0.0M Revenue, $(50.83) EPS on $(39.0) M Net Loss](https://longbridge.com/zh-CN/news/278384128.md) - [Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs](https://longbridge.com/zh-CN/news/278102320.md) - [Q1 EPS Forecast for Amylyx Pharmaceuticals Lifted by Analyst](https://longbridge.com/zh-CN/news/278095132.md)